Brief: Theranexus: Success Of Phase 2 Study For THN102
31/03/2020 17:18
March 31 (Reuters) - THERANEXUS SA ALTHX.PA :
* SUCCESS OF ITS PHASE 2 STUDY FOR THN102 IN THE PARKINSON
DISEASE
* THN102 MEETS PRIMARY ENDPOINT
* THN102: EXCELLENT TOLERANCE IN PARKINSON'S DISEASE
PATIENTS
Source text for Eikon: ID:nACT62757
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease